These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1701585)

  • 21. Standardization of immunoassays for prostate specific antigen. A different view based on experimental observations.
    Stamey TA; Prestigiacomo AF; Chen Z
    Cancer; 1994 Sep; 74(6):1662-6. PubMed ID: 7521782
    [No Abstract]   [Full Text] [Related]  

  • 22. Western blot assay for prostate-specific membrane antigen in serum of prostate cancer patients.
    Rochon YP; Horoszewicz JS; Boynton AL; Holmes EH; Barren RJ; Erickson SJ; Kenny GM; Murphy GP
    Prostate; 1994 Oct; 25(4):219-23. PubMed ID: 8084837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
    Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
    N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario.
    Prestigiacomo AF; Lilja H; Pettersson K; Wolfert RL; Stamey TA
    J Urol; 1996 Aug; 156(2 Pt 1):350-4. PubMed ID: 8683677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer.
    Benson MC; Whang IS; Pantuck A; Ring K; Kaplan SA; Olsson CA; Cooner WH
    J Urol; 1992 Mar; 147(3 Pt 2):815-6. PubMed ID: 1371554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of prostate-specific antigen in serum by immunoradiometric assay.
    Lindstedt G; Jacobsson A; Lundberg PA; Hedelin H; Pettersson S; Unsgaard B
    Clin Chem; 1990 Jan; 36(1):53-8. PubMed ID: 1688745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen.
    Black MH; Magklara A; Obiezu CV; Melegos DN; Diamandis EP
    Clin Chem; 1999 Jun; 45(6 Pt 1):790-9. PubMed ID: 10351987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum prostate-specific antigen and prostate pathology in men having simple prostatectomy.
    Brawer MK; Rennels MA; Nagle RB; Schifman R; Gaines JA
    Am J Clin Pathol; 1989 Dec; 92(6):760-4. PubMed ID: 2480060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Presence of PSA auto-antibodies in men with prostate abnormalities (prostate cancer/benign prostatic hyperplasia/prostatitis).
    Lokant MT; Naz RK
    Andrologia; 2015 Apr; 47(3):328-32. PubMed ID: 24620795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Significance of the PSA-concentration for the detection of prostate cancer].
    Stachon A
    Pathologe; 2005 Nov; 26(6):469-72. PubMed ID: 16195861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Haptoglobin-beta chain defined by monoclonal antibody RM2 as a novel serum marker for prostate cancer.
    Saito S; Murayama Y; Pan Y; Taima T; Fujimura T; Murayama K; Sadilek M; Egawa S; Ueno S; Ito A; Ishidoya S; Nakagawa H; Kato M; Satoh M; Endoh M; Arai Y
    Int J Cancer; 2008 Aug; 123(3):633-40. PubMed ID: 18464263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gamma-seminoprotein--a new tumour marker in prostatic cancer? Results of a pilot study.
    Maier U; Simak R
    Br J Urol; 1990 May; 65(5):509-12. PubMed ID: 1693867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens.
    Kuriyama M; Wang MC; Lee CL; Killian CS; Papsidero LD; Inaji H; Loor RM; Lin MF; Nishiura T; Slack NH; Murphy GP; Chu TM
    J Natl Cancer Inst; 1982 Jan; 68(1):99-105. PubMed ID: 6172628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumour markers in prostatic cancer.
    Cooper EH
    Scand J Clin Lab Invest Suppl; 1991; 206():42-51. PubMed ID: 1719610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of metallopanstimulin and oncogenesis in human prostatic carcinoma.
    Fernandez-Pol JA; Fletcher JW; Hamilton PD; Klos DJ
    Anticancer Res; 1997; 17(3A):1519-30. PubMed ID: 9179190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Discrepancy between the serum levels of gamma seminoprotein and prostate-specific antigen in patients with prostatic neoplasms. Both true or either untrue].
    Fujino A; Mukai N; Kawakami T; Yokoyama E; Mashimo S; Endo T; Ishibashi A; Koshiba K; Aoki Y; Itoh H
    Nihon Hinyokika Gakkai Zasshi; 1991 Apr; 82(4):541-50. PubMed ID: 1711133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The antibody response to Propionibacterium acnes is an independent predictor of serum prostate-specific antigen levels in biopsy-negative men.
    Shannon BA; Cohen RJ; Garrett KL
    BJU Int; 2008 Feb; 101(4):429-35. PubMed ID: 17850358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate-specific antigen in management of prostatic carcinoma.
    Brawer MK; Lange PH
    Urology; 1989 May; 33(5 Suppl):11-6. PubMed ID: 2469244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate specific antigen and prostate specific antigen density. Roles in patient evaluation and management.
    Benson MC; Olsson CA
    Cancer; 1994 Sep; 74(6):1667-73. PubMed ID: 7521783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate-specific antigen in prostate cancer.
    Kuriyama M
    Int J Biol Markers; 1986; 1(2):67-76. PubMed ID: 2448397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.